Researchers at Stanford have leveraged spatial proteomic analysis to identify biomarkers with immediate implications for HER2-positive breast cancer treatment decision making and patient stratification.
Stanford researchers in The Tang Group have developed a reproducible, high throughput device that dices tissue into uniformly sized sub-millimeter sample fragments.
Running chemotherapeutic drug screens on tumor biopsies ex vivo has the potential to increase patient survival by personally matching them to the drug which is the most effective against their particular tumor.